Literature DB >> 18406675

The pathogenesis of the bone disease of multiple myeloma.

Claire M Edwards1, Junling Zhuang, Gregory R Mundy.   

Abstract

Multiple myeloma is a fatal hematologic malignancy associated with clonal expansion of malignant plasma cells within the bone marrow and the development of a destructive osteolytic bone disease. The principal cellular mechanisms involved in the development of myeloma bone disease are an increase in osteoclastic bone resorption, and a reduction in bone formation. Myeloma cells are found in close association with sites of active bone resorption, and the interactions between myeloma cells and other cells within the specialized bone marrow microenvironment are essential, both for tumor growth and the development of myeloma bone disease. This review discusses the many different factors which have been implicated in myeloma bone disease, including the evidence for their role in myeloma and subsequent therapeutic implications.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18406675      PMCID： PMC2474770          DOI： 10.1016/j.bone.2008.01.027

Source DB:  PubMed          Journal:  Bone        ISSN： 1873-2763            Impact factor:   4.398


  78 in total

1.  Evidence for the secretion of an osteoclast stimulating factor in myeloma.

Authors:  G R Mundy; L G Raisz; R A Cooper; G P Schechter; S E Salmon
Journal:  N Engl J Med       Date:  1974-11-14       Impact factor: 91.245

2.  Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).

Authors:  Marianna Politou; Evangelos Terpos; Athanasios Anagnostopoulos; Richard Szydlo; Michael Laffan; Mark Layton; Jane F Apperley; Meletios-Athanasios Dimopoulos; Amin Rahemtulla
Journal:  Br J Haematol       Date:  2004-09       Impact factor: 6.998

3.  Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis.

Authors:  Yoshihisa Mori; Nobuaki Shimizu; Mark Dallas; Maryla Niewolna; Beryl Story; Paul J Williams; Gregory R Mundy; Toshiyuki Yoneda
Journal:  Blood       Date:  2004-05-11       Impact factor: 22.113

4.  Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

Authors:  Masahiro Abe; Kenji Hiura; Javier Wilde; Atsushi Shioyasono; Keiji Moriyama; Toshihiro Hashimoto; Shinsuke Kido; Takashi Oshima; Hironobu Shibata; Shuji Ozaki; Daisuke Inoue; Toshio Matsumoto
Journal:  Blood       Date:  2004-06-08       Impact factor: 22.113

Review 5.  SDF-1 and CXCR4 in normal and malignant hematopoiesis.

Authors:  J Juarez; L Bendall
Journal:  Histol Histopathol       Date:  2004-01       Impact factor: 2.303

6.  Cancer and the microenvironment: myeloma-osteoclast interactions as a model.

Authors:  Shmuel Yaccoby; Michele J Wezeman; Aminah Henderson; Michele Cottler-Fox; Qing Yi; Bart Barlogie; Joshua Epstein
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

7.  IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.

Authors:  Jun Won Lee; Ho Yeon Chung; Lori A Ehrlich; Diane F Jelinek; Natalie S Callander; G David Roodman; Sun Jin Choi
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

8.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

9.  BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.

Authors:  Georges Rawadi; Béatrice Vayssière; Fred Dunn; Roland Baron; Sergio Roman-Roman
Journal:  J Bone Miner Res       Date:  2003-10       Impact factor: 6.741

10.  Quantitative histology of myeloma-induced bone changes.

Authors:  A Valentin-Opran; S A Charhon; P J Meunier; C M Edouard; M E Arlot
Journal:  Br J Haematol       Date:  1982-12       Impact factor: 6.998
View more
  61 in total

1.  Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.

Authors:  Yang Yang; Yongsheng Ren; Vishnu C Ramani; Li Nan; Larry J Suva; Ralph D Sanderson
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

2.  Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Authors:  Jerome Moreaux; Dirk Hose; Alboukadel Kassambara; Thierry Reme; Philippe Moine; Guilhem Requirand; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

3.  Multimorbidity in women with and without osteoporosis: results from a large US retrospective cohort study 2004-2009.

Authors:  C D O'Malley; N Tran; C Zapalowski; N Daizadeh; T P Olenginski; J A Cauley
Journal:  Osteoporos Int       Date:  2014-05-24       Impact factor: 4.507

Review 4.  The bone marrow stroma in hematological neoplasms--a guilty bystander.

Authors:  Claudio Tripodo; Sabina Sangaletti; Pier P Piccaluga; Sonam Prakash; Giovanni Franco; Ivan Borrello; Attilio Orazi; Mario P Colombo; Stefano A Pileri
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

5.  Physical activity for cancer patients: clinical risk assessment for exercise clearance and prescription.

Authors:  Jamie F Burr; Roy J Shephard; Lee W Jones
Journal:  Can Fam Physician       Date:  2012-09       Impact factor: 3.275

6.  PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.

Authors:  Mulu Z Tesfay; Amber C Kirk; Elizabeth M Hadac; Guy E Griesmann; Mark J Federspiel; Glen N Barber; Stephen M Henry; Kah-Whye Peng; Stephen J Russell
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

7.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

8.  Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.

Authors:  Claire M Edwards; Seint T Lwin; Jessica A Fowler; Babatunde O Oyajobi; Junling Zhuang; Andreia L Bates; Gregory R Mundy
Journal:  Am J Hematol       Date:  2009-05       Impact factor: 10.047

9.  Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma.

Authors:  Ya-Wei Qiang; Yu Chen; Nathan Brown; Bo Hu; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Br J Haematol       Date:  2009-11-24       Impact factor: 6.998

10.  Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Authors:  J Akech; J J Wixted; K Bedard; M van der Deen; S Hussain; T A Guise; A J van Wijnen; J L Stein; L R Languino; D C Altieri; J Pratap; E Keller; G S Stein; J B Lian
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.